Sign up to save your podcasts
Or
Share How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
How to Treat Renal Cell Carcinoma (RCC) using a Treatment Algorithm with Dr. Katy Beckermann
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.
In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:
• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.
• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.
• The importance of patient characteristics and IMDC risk categorization in treatment decisions.
• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.
• The role of ctDNA, PD-L1 testing, and NGS in RCC.
Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.
YouTube: https://youtu.be/Bbv9N7-YKIM
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
View all episodes
By Oncology Brothers
4.9
4242 ratings
Join us for an insightful episode of the Oncology Brothers podcast as we dive deep into the world of renal cell carcinoma (RCC) with Dr. Katy Beckermann, the Medical GU Director of Cancer Research at Tennessee Oncology.
In this episode, hosts Drs. Rahul & Rohit Gosain, practicing medical oncologists, discuss the latest advancements in RCC treatment, including:
• The role of Pembrolizumab in the adjuvant setting based on the Keynote 564 study and its implications for early-stage disease.
• Current treatment paradigms for metastatic RCC, including dual checkpoint inhibitors, TKI with immunotherapy, and single-agent options.
• The importance of patient characteristics and IMDC risk categorization in treatment decisions.
• Insights into sequencing therapies, including the use of Belzutifan for refractory disease and the management of side effects.
• The role of ctDNA, PD-L1 testing, and NGS in RCC.
Whether you're a community oncologist or simply interested in the latest in cancer care, this episode is packed with valuable information to help you stay informed and provide the best care for your patients.
YouTube: https://youtu.be/Bbv9N7-YKIM
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and leave a review to let us know how we're doing and how we can continue to support you in the community!
More shows like Oncology Brothers: Practice-Changing Cancer Discussions
View all
Journal of Clinical Oncology (JCO) Podcast
39 Listeners
Research To Practice | Oncology Videos
120 Listeners
ASCO Daily News
58 Listeners
Pod Save America
87,249 Listeners
Core IM | Internal Medicine Podcast
1,148 Listeners
The ONS Podcast
206 Listeners
OncoPharm
187 Listeners
ASCO Guidelines
45 Listeners
OncLive® On Air
22 Listeners
Lung Cancer Considered
26 Listeners
Oncology Today with Dr Neil Love
57 Listeners
Oncology On The Go
4 Listeners
Blood Cancer Talks
51 Listeners
Two Onc Docs
192 Listeners
Oncology for the Inquisitive Mind
4 Listeners